The development goals of medicine in the next five years have been clarified, and it is recommended to focus on this core line

The "14th Five-Year Plan for the Development of the Pharmaceutical Industry" (referred to as the "Plan") clarifies the development goals of the pharmaceutical industry in the next five years: by 2025, the main economic indicators will achieve medium-to-high-speed growth, the innovation achievements in frontier fields will be outstanding, the innovation power will be enhanced, and the industrial The level of chain modernization has been significantly improved, the supply guarantee system for pharmaceuticals and equipment has been further improved, and the level of internationalization has been improved in an all-round way
.
Specific to economic indicators, the "Planning" proposes that economies of scale will increase steadily, and the average annual growth rate of operating income and total profit will remain above 8%; the proportion of added value in all industries will increase to about 5%; the concentration of leading enterprises in the industry will be further improved.
; The industry-wide R&D investment has an average annual growth rate of more than 10%
.
With the official release of the "Planning", the industry stated that under the premise of controlling medical insurance costs, innovation and internationalization will be the core main lines of the future industry.
It is recommended to focus on innovation-driven companies and pharmaceutical companies with internationalization capabilities
.
It is recommended to pay attention to WuXi AppTec, Junshi Biotechnology, BeiGene and other companies
.
Among them, WuXi PharmaTech has always implemented the strategy of "following molecules", and the integrated chemical business (WuXi Chemistry) segment will continue to build an "integrated, end-to-end" CRDMO (Contract Research, Development and Production Organization) business, order demand Exuberant, which also drove the accelerated growth of the company's full-year sales in 2021
.
According to the data, in 2021, WuXi AppTec’s attributable net profit will increase by 72.
19% year-on-year to 5.
0972 billion yuan
.
The company expects that the revenue growth rate of the chemical business segment in 2022 will nearly double compared to the revenue growth rate in 2021; the revenue growth rate of the testing business in 2022 will continue the momentum of recent years
.
The cell and gene therapy CTDMO business unit (WuXiATU) will be a turning point for business development in 2022, and the company expects revenue growth to exceed the industry growth rate
.
Regarding WuXi AppTec's investment logic, some analysts said that 1.
Laboratories and CDMOs in China maintained high growth, and clinical CRO increased quarter by quarter
.
2.
The company actively strengthens the implementation of the long-tail strategy to empower domestic small and medium-sized pharmaceutical companies to develop and produce innovative drugs
.
3.
The speed at which innovative drugs are included in medical insurance continued to increase, which in turn drove the demand for domestic CDMO orders to grow
.
Junshi Biosciences is an innovation-driven biopharmaceutical company with complete industry chain capabilities ranging from innovative drug discovery, global clinical research and development, large-scale production to commercialization
.
With the continuous enrichment of the company's product pipeline and further exploration of drug combination therapy, the company's innovation field will continue to expand to include small molecule drugs, antibody drug conjugates (ADC), bifunctional fusion proteins, cell therapy and other types drug development and the exploration of next-generation innovative treatments for cancer and autoimmune diseases
.
According to the data, in 2021, Junshi Bio’s total operating income will increase by 151.
71% year-on-year, reaching 4,014,497,300 yuan
.
Analysts said that BeiGene has grown into a global biotechnology company with independent research and development supplemented by global cooperation
.
Its self-developed innovative drug matrix supports high revenue growth, licensing and cooperative research and development further expand the layout of differentiated products, and international clinical trial centers and production bases maximize platform creativity.
BeiGene, with strong comprehensive strength, has long-term value reserves attention
.
Data show that BeiGene’s full-year revenue in 2021 will increase by 281% year-on-year to $1.
2 billion
.
In an environment of rising capital costs in the industry, the company's cash, cash equivalents, restricted funds and short-term investments increased by 42% year-on-year to US$6.
62 billion, strongly supporting the company's innovation-driven competitive advantage
.
As a domestic innovative drug international enterprise, BeiGene has further verified its technological innovation capabilities, commercialization capabilities and globalization process with the commercialization of core products and the differentiated layout of innovative drug R&D pipelines
.
At present, the investment value of the pharmaceutical industry is prominent.
The industry said that innovation-driven companies and pharmaceutical companies with internationalization capabilities deserve continuous attention.
In addition, it is recommended to pay attention to the 2021 annual report and the 2022 first quarter report.
High-quality targets that are expected to grow or exceed expectations, as well as the Chinese medicine sector Wait
.
From the perspective of the traditional Chinese medicine sector, the release of the "Guiding Opinions on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" shows the country's determination to inherit and innovate the development of traditional Chinese medicine, which will bring a positive effect to the traditional Chinese medicine industry
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.